Invesco Ltd. Acquires 321,173 Shares of Amgen Inc. $AMGN

Invesco Ltd. raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 7.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,788,460 shares of the medical research company’s stock after buying an additional 321,173 shares during the period. Invesco Ltd.’s holdings in Amgen were worth $1,567,311,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. First Growth Capital LLC acquired a new position in shares of Amgen during the 4th quarter worth about $681,000. Corient Private Wealth LLC increased its position in shares of Amgen by 69.5% in the fourth quarter. Corient Private Wealth LLC now owns 591,748 shares of the medical research company’s stock valued at $193,685,000 after acquiring an additional 242,649 shares during the last quarter. Smith Asset Management Co. LLC bought a new stake in Amgen during the fourth quarter worth about $216,000. CrossGen Wealth LLC acquired a new position in Amgen during the fourth quarter valued at approximately $74,000. Finally, Strive Financial Group LLC acquired a new position in Amgen during the fourth quarter valued at approximately $2,409,000. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

NASDAQ:AMGN opened at $337.60 on Friday. Amgen Inc. has a 12-month low of $267.83 and a 12-month high of $391.29. The firm has a market capitalization of $182.21 billion, a price-to-earnings ratio of 23.49, a P/E/G ratio of 3.43 and a beta of 0.42. The stock’s 50 day moving average price is $340.96 and its two-hundred day moving average price is $345.81. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. The company had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts anticipate that Amgen Inc. will post 22.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on AMGN. Morgan Stanley boosted their price target on Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 9th. Truist Financial raised their target price on shares of Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a research note on Friday, May 1st. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Mizuho upped their price target on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research report on Tuesday. Finally, Wells Fargo & Company increased their price target on shares of Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a research note on Thursday, March 19th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Amgen has an average rating of “Hold” and an average target price of $354.42.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.85% of the stock is owned by corporate insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.